Investigational drug · Phase 3
ART
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for HIV Infections, HIV-1 Infection.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
1,516
Any phase or sponsor naming "ART"
First trial start
2023
Feb 20, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ART", any sponsor or status.
Conditions studied
As listed on its trial records.
- HIV Infections
- HIV-1 Infection
Approved drugs for the same conditions: HIV · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "ART" as an intervention, largest first.
- Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV IncidencePivotal-lookingCompleted
ANRS, Emerging Infectious DiseasesGovernment (non-federal)
NCT01509508 · 28,153 participants · Start Mar 2012 · Primary completion Jun 2016
Drug: Immediate ARV treatment initiation with TDF/FTC/EFV · For: HIV Infection
Sites: Hlabisa, South Africa
- TB (Tuberculosis) Preventive Therapy for HIV Patients With Access to HAART (Highly Active Antiretroviral Therapy)Pivotal-lookingCompleted
Johns Hopkins UniversityAcademic, hospital or other
NCT00107887 · 17,415 participants · Start Jun 2005 · Primary completion Dec 2010
Drug: INH preventive therapy; TST (tuberculin skin test) · For: Tuberculosis; HIV Infections
Sites: Rio de Janeiro, Brazil
- European Pregnancy and Paediatric Infections Cohort Collaboration: Paediatric ProtocolStatus unknown
PENTA FoundationResearch network
NCT04677842 · 10,000 participants · Start Jan 1, 2013 · Primary completion Nov 11, 2020
Drug: ART Therapy · For: HIV Infections; Tuberculosis Infection; Hepatitis C and 1 more
- Testing and Linkage to Care for Injecting Drug Users in KenyaPivotal-lookingCompleted
Yale UniversityAcademic, hospital or other
NCT01557998 · 9,449 participants · Start May 2012 · Primary completion Apr 30, 2016
Drug: HCV+PWID · For: HIV Infection; HCV Coinfection
Sites: Nairobi, Kenya
Shin Poong Pharmaceutical Co. Ltd.Industry
NCT03201770 · 8,572 participants · Start Jun 22, 2017 · Primary completion Apr 10, 2019
Drug: pyronaridine artesunate · For: Malaria,Falciparum
Sites: Yaoundé, Cameroon; Bouaké, Côte d’Ivoire; Kinshasa, Democratic Republic of the Congo · 5 sites in all
- Reducing Mortality in Adults With Advanced HIV Disease (REVIVE)Pivotal-lookingRecruiting
Population Health Research InstituteAcademic, hospital or other
NCT05580666 · 8,000 participants (planned) · Start May 8, 2023 · Primary completion Nov 30, 2028
Drug: Azithromycin Oral Tablet; Placebo oral tablet · For: HIV Disease Progression
Sites: Abidjan, Côte d’Ivoire; Ādama, Ethiopia; Āsela, Ethiopia · 52 sites in all
- FocaL Mass Drug Administration for Vivax Malaria EliminationPivotal-lookingRecruiting
University of California, San FranciscoAcademic, hospital or other
NCT05690841 · 7,530 participants (planned) · Start Oct 14, 2024 · Primary completion May 1, 2027
Drug: Focal Mass Drug Administration (fMDA) · For: Plasmodium Vivax Malaria; Malaria
Sites: Iquitos, Peru
- Investigating the Optimal Management of Dolutegravir ResistanceActive, not recruiting
University of NairobiAcademic, hospital or other
NCT06762054 · 6,624 participants · Start Mar 3, 2025 · Primary completion Feb 15, 2027
Drug: Continue DTG-based antiretroviral therapy · For: HIV-1-infection
Sites: Kisumu, Kenya; Mombasa, Kenya; Nairobi, Kenya · 9 sites in all
- Assessment of Use of Rapid Diagnostic Testing in the Context of Home Management With ACTsPivotal-lookingCompleted
Mbarara University of Science and TechnologyAcademic, hospital or other
NCT00720811 · 6,456 participants · Start Oct 2009 · Primary completion Jan 2012
Drug: Artemether-lumefantrine combination; amoxycillin and 2 more · For: Malaria; Pneumonia
Sites: Saponé, Burkina Faso; Kassane, Ghana; Iganga, Uganda · 4 sites in all
- Mass-Drug Administration to Reduce Malaria TransmissionPivotal-lookingCompleted
Radboud University Medical CenterAcademic, hospital or other
NCT00509015 · 6,000 participants (planned) · Start Feb 2008 · Primary completion Aug 2008
Drug: Sulphadoxine-pyrimethamine (day 1: 500mg S&25mg P/20 kg); Artesunate (day 1,2,3: 4 mg/kg) and 2 more · For: Malaria, Falciparum
Sites: Moshi, Tanzania
Newest research
PubMed records naming it or its code names, newest first.
- "Sailing Two Boats" the fragmented identity of working women and the hidden labor of infertility: a qualitative analysis.
Dhar S, Poojari VG, Adiga P, et al. · J Psychosom Obstet Gynaecol 2027
- Prevalence of neural tube defects and major external structural abnormalities by antiretroviral treatment regimen in Botswana in 2014-22:ߙa birth outcomes surveillance study.
Zash R, Diseko M, Holmes LB, et al. · Lancet Glob Health 2027
- Local-Global Spherical Sliced Wasserstein Graph Kernel for Schizophrenia Identification.
Jia X, Chang X, Chang J, et al. · Int J Neural Syst 2027
- Exploiting Phase-Sliding Oscillations for Robust Asynchronous Brain-Computer Interface Control.
Li J, Wen S, Hu J, et al. · Int J Neural Syst 2027
- Breaking the degenerative triad: Microenvironment reprogramming biomaterials for intervertebral disc regeneration.
Zhao X, Han X, Hu Z, et al. · Bioact Mater 2027
- Artemisinin-derived radicals trigger TGFβ oxidation and degradation for alopecia therapy.
Wang R, Wang C, Liu C, et al. · Biomaterials 2027
Also in development for HIV Infections
- rHuPH20Phase 35 trials
Bristol Myers Squibb · Melanoma, Relapsing-remitting Multiple Sclerosis, Clear Cell Renal Cell Carcinoma
- TeropavimabTAB, GS-5423Phase 33 trials
Gilead Sciences · HIV-1 Infection, HIV Infections, HIV-1-infection
- ZinlirvimabGS-2872, ZABPhase 33 trials
Gilead Sciences · HIV-1 Infection, HIV Infections, HIV-1-infection
- 2 NRTIsPhase 32 trials
Merck & Co. · Human Immunodeficiency Virus (HIV) Infection, Infection, Human Immunodeficiency Virus, HIV Infections
- ABC3TC STR, 3TC immediate releasePhase 32 trials
GSK · HIV Infections
- DTGPhase 32 trials
Jiangsu Aidea Pharmaceutical Group Co., Ltd. · Infection, Human Immunodeficiency Virus, HIV Infections
- BMS-663068Phase 31 trial
GSK · HIV Infections
- JL18008Phase 21 trial
Jecho Biopharmaceuticals Co., Ltd. · HIV Infections
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from GSK.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.